Phaseline

Companies › TaiRx

TaiRx: clinical trials, targets and expected readouts

3 active drug programs in 5 registered trials: 4 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CVM-1118–Phase 2Neuroendocrine Tumors; Hepatocellular Carcinoma; HCC - Hepatocellular CarcinomaDec 2026
Sintilimab
Programmed cell death protein 1 antagonist
PDCD1Phase 2HCC - Hepatocellular CarcinomaDec 2027
TRX-920 Oral Gel
Topoisomerase I inhibitor (SN38, active metabolite of irinotecan)
CAMPTPhase 1Advanced Solid TumorDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03600233CVM-1118Phase 2Neuroendocrine TumorsOncologySep 2024
NCT05257590CVM-1118Phase 2Hepatocellular CarcinomaOncologyDec 2026
NCT06143774TRX-920 Oral GelPhase 1Advanced Solid TumorOncologyDec 2026
NCT07521852CVM-1118Phase 2HCC - Hepatocellular CarcinomaOncologyDec 2027
NCT07521852SintilimabPhase 2HCC - Hepatocellular CarcinomaOncologyDec 2027

Targets

CAMPT (1) PDCD1 (1)

Companies with the same targets

Akeso Sichuan Baili Pharmaceutical Innovent Biologics (Suzhou) Shanghai Henlius Biotech AstraZeneca Shenyang Sunshine Pharmaceutical Regeneron Pharmaceuticals Ono Pharmaceutical Mabwell (Shanghai) Bioscience Johnson & Johnson (Janssen)

Companies built like this

CStone Pharmaceuticals CSPC Megalith Biopharmaceutical CrystalGenomics Guangzhou Gloria Biosciences Tianjin ConjuStar Biologics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.